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Background: We earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically
with 1,25-dihydroxyvitamin D3 in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or
in combination with vitamin D3 for induction of LL-37 expression in immune cells and enhancement of
antimycobacterial activity in monocyte-derived macrophages (MDM).
Methods: Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I),
500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)},
PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days. Blood was collected on
day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes
(NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by
qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D3 levels were determined by ELISA. MDM-mediated killing
of Mycobacterium tuberculosis (Mtb) (H37Rv) was performed by conventional culture method.
Results: MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I
showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05). Both Group-I and -II exhibited higher
levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035). Increased induction of peptide was
observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05), while Group-IV
showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04). Intracellular killing of Mtb on day-4
was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05).
Conclusion: The results demonstrate that 500 mg b.d. PB with 5000 IU o.d. vitamin D3 is the optimal dose for the
induction of LL-37 in macrophages and lymphocytes and intracellular killing of Mtb by macrophages. Hence, this
dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active
pulmonary TB (NCT01580007).
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Tuberculosis (TB), caused by Mycobacterium tuberculosis
(Mtb), is a predominant public health problem worldwide
and responsible for about 3 million deaths annually [1].
The prevalence of TB is increasing due to the spread of
antibiotic-resistant strains of Mtb [2,3]. The deleterious
consequences of co-infection with HIV is the emergence of
XDR (extremely drug resistance) cases in Africa and other
countries in recent years [4]. Advances in anti-tuberculous
therapies and alternative treatment strategies are urgently
required for the treatment of TB patients and exposed
individuals at high risk of developing TB [5,6].
Antimicrobial peptides (AMPs) are important effectors
of the innate defense system [7]. AMPs can limit growth
and virulence properties of microbes directly or indirectly
by enhancing the host immune system. Induction of
endogenous AMP expression by administration of extrinsic
compounds may be an attractive approach for alternative
therapy in combating infectious diseases. Cathelicidins [8]
and Defensins [9] and are major classes of AMPs, in mam-
mals LL-37 is the only human cathelicidin and is expressed
by both circulating white blood cells and epithelial surfaces
including lungs [10].
The active form of vitamin D3 was shown to regu-
late the production of AMPs, i.e. cathelicidin LL-37,
which plays an important role in the innate immune
defense against infections including TB [11,12].
These studies have encouraged many investigators to
initiate vitamin D trials in TB patients with renewed
enthusiasm [5,13-15] (NCT01130311; NCT00507000;
NCT00366470; NCT00677339; NCT00918086). In a
systemic review and meta-analysis of observational studies,
evidence of an association with vitamin D3 deficiency and
active TB was demonstrated [16].
Our group has earlier shown that cathelicidin is
downregulated in the mucosal epithelia during acute
diarrhea [17,18] and in infection with Neisseria gonorrhea
[19]. We showed that the downregulation of the rabbit
cathelicidin (CAP-18) in the large intestine can be
counteracted by oral treatment with sodium butyrate, a
short chain fatty acid and phenylbutyrate (PB), an analogue
of butyrate in experimental model of shigellosis [17,20]. PB
further counteracted the downregulation of CAP-18 in the
lung and tracheal epithelia through systemic effects [20].
We further demonstrated that PB can induce LL-37 expres-
sion synergistically with 1,25-dihydroxyvitamin D3 at both
protein and mRNA levels in a lung epithelial cell line [21].
It is thus likely that oral supplementation with PB will boost
innate immunity in the lung mucosa by increasing expres-
sion of innate defense proteins. A dose of PB corresponding
to that used for rabbits [20] for induction of cathelicidin
was calculated by allometric scaling for use in adults. The
calculations suggested that an effective dose for a 60 kg
human would be approximately 600 mg of PB twice daily.Our aim in this study was to determine the optimal dose
of PB with or without vitamin D3 in adults for induction of
LL-37 in immune cells and increase in functional capacity
of macrophages in killing of Mtb. Thus, healthy adult
volunteers were treated with different doses of PB and in
combination with a defined concentration of vitamin D3.
Methods
Study design
Healthy participants (age range 18 to 55 yrs; n = 15)
working at International Centre for Diarrheal Disease
Research, Bangladesh (icddr,b) and National Institute of
the Diseases of the Chest and Hospital (NIDCH), Dhaka,
Bangladesh were recruited in this study. The study was
approved by the Ethical Review Committee of icddr,b.
Informed consent was obtained from the participants after
explaining the nature and purpose of the study. Individuals
were excluded if they had symptoms or clinical signs of
infection, e.g. fever or diarrhea within the last 2–3 months,
if taking corticosteroids, diuretics, or supplementary
vitamin D3 (either alone or as part of a multivitamin prep-
aration). The volunteers were asked to abstain from taking
any vitamins or supplements for at least two weeks prior to
and during the study period. There were five groups, each
consisting of 3 participants. Groups-I, -II and -III received
the following doses respectively: 250 mg, 500 mg or 1 g of
PB b.d. plus 5000 IU vitamin D3 o.d. for 4 consecutive days.
Group-IV received 500 mg PB b.d. and Group-V received
5000 IU vitamin D3 o.d. for 4 consecutive days. All healthy
volunteers were followed for another 4 days after the treat-
ment to monitor possible side effects. Four-phenylbutyrate
(Tributyrate) and the placebo tablet were obtained from
Fyrklövern Scandinavia AB, Mönsterås, Sweden; vitamin D3
(Vigantol oil) and the placebo oil were obtained from
Merck KGaA, Darmstadt, Germany. The healthy volunteer
trial was conducted to determine an optimal dose for the
clinical trial in TB patients (NCT01580007).
Blood collection and cell culture
Peripheral blood was collected at 3 time points (day-0,
day-4 and day-8) from each participant (25 mL/individual).
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood by Ficoll-Hypaque density gradient cen-
trifugation and plasma was collected and stored at −20°C
for later measurement of 25-hydroxyvitamin D3, calcium,
(serum glutamate pyruvate transaminase (SGPT; liver
function marker) and creatinine (kidney function marker).
The PBMC pellet was washed and suspended in a culture
medium containing 10% autologous plasma in RPMI-1640,
1% L-glutamine, 1% sodium pyruvate, 0.5% amphotericin B
and 1% penicillin-streptomycin (Gibco, Grand Island, NY,
USA) and plated in two parallel 4-well tissue culture plates
(NUNC, Roskilde, Denmark). One tissue culture plate was
utilized for analyses of LL-37 peptide and transcript and
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killing assay.
PBMCs were counted and incubated in culture plates
for 3 days. Thereafter, supernatant containing the non-
adherent cells (mostly lymphocytes, 80-90%) was removed,
centrifuged to collect the clear supernatant which was the
extracellular fluid (ECF) of PBMC. The non-adherent
lymphocytes were treated with saponin for 10 minutes,
centrifuged and supernatant collected as intracellular fluid
(ICF) from lymphocytes. Supernatant and cell pellet were
stored for further analysis. The remaining adherent cells in
the culture plate were MDM, which were harvested and
treated with saponin. After centrifugation, supernatant
(ICF) and cells were stored until further analysis. RNALater
(Qiagen GmbH, Hilden, Germany) was added to the
cell pellet for RNA extraction. In another experi-
ment, one part of PBMC was stimulated ex vivo with
Bacille Calmette-Guerin, (BCG, 10 μg/mL: Japan BCG
Laboratory, Tokyo, Japan) for 3 days, supernatant con-
taining the non-adherent cells was removed, centrifuged to
collect the clear supernatant which was the ECF of BCG
stimulated PBMC.
Vitamin D3, calcium, albumin, SGPT and creatinine in
plasma
In plasma, 25-hydroxyvitamin D3 was measured by a
commercial ELISA kit (IDS, Fountain Hills, Arizona,
USA) that determines 25-hydroxyvitamin D3 (100%), 25-
hydroxyvitamin D2 (75%) and 24,25-dihydroxyvitamin D3
(≥100%). Calcium, albumin and creatinine were assessed
by Roche automated clinical chemistry analyzer, Hitachi
902. Serum glutamate-pyruvate transaminase (SGPT)
was measured by Beckman-Coulter AU680 (Japan).
LL-37 ELISA
LL-37 levels in ICF of macrophage and lymphocyte lysates
as well as in ECF of PBMC and BCG stimulated PBMC
were measured by ELISA. Duplicate samples were tested
and concentrations were calculated using a standard
curve generated from synthetic LL-37 (Innovagen,
Lund, Sweden). Brief procedure of ELISA is as follow.
Polystyrene microtiter plates (Maxisorp by NUNC,
Naperville, IL, USA) were coated with monoclonal anti-
LL-37 [22] (5 μg/ml) in carbonate buffer (15 mM sodium
carbonate, 35 mM sodium bicarbonate and 0.02% sodium
azide [pH 9.6]) and incubated overnight at 4°C. After wash-
ing, non-specific binding was blocked with 0.1% gelatin in
tris-buffered saline (pH 7.5) for 1 hour at RT. Standards
and samples were then added and incubated overnight at
4°C. Biotinylated rabbit anti-LL-37 (1 μg/mL) (Innovagen)
was added and incubated for 2 h at room temperature
(RT), followed by the incubation with Streptavidin-alkaline
phosphatase conjugate (Chemicon, Melbourne, Australia)
for another 2 h at RT. Four-methylumbelliferyl phosphatewas used as substrate (Molecular Probes, Europe BV,
Leiden, The Netherlands) and fluorescence was measured
at an excitation wavelength of 360 nm and emission
wavelength of 450 nm.
Quantitative real time RT-PCR amplification of LL-37
mRNA
RNA was extracted from macrophages and lymphocytes
utilizing RNeasy Mini kit as described by the manufacturer
(Qiagen GmbH). cDNA was synthesized using Superscript
III First-Strand Synthesis System (Invitrogen, Grand Island,
NY, USA). The CAMP gene encoding transcript LL-37
relative to the housekeeping 18S rRNA was measured in
triplicate from the cDNA samples by real-time quantitative
RT-PCR using CFX96 Real-Time PCR Detection Systems
(Bio-Rad,) and the 18 s rRNA–housekeeping gene kit
(Applied Biosystems, Foster City, CA, USA). The se-
quences of forward and reverse primers for LL-37
transcript were 5’-TCACCAGAGGATTGTGACTTCAA-3’
and 5’-TGAGGGTCACTGTCCCCATAC-3’, respectively
(Primer Express; Applied Biosystems). The results were
analyzed by using the relative standard method [19].
Macrophage mediated killing of Mycobacterium
tuberculosis
MDM in the culture plates were infected with previously
prepared log phased Mtb H37Rv strain (from Tuberculosis
Research Center, Chennai, India) in culture medium
without antibiotics [23]. Initially 3 different multiplicity of
infection (MOI; 1:10; 1:25 and 1:50) were tested and the
ratio of 1:25 was found to be the optimal MOI, resulting in
a clear bacterial killing. After 2 hours of exposure the
culture plates were washed 3 times with warm RPMI to
remove the extracellular bacteria and the infected MDM
were cultured for three additional days in a medium with
autologous plasma and antibiotics (penicillin-streptomycin,
amphotericin B) (Gibco). Thereafter, the cells were lysed
with 0.3% saponin-PBS and vigorous pipetting to collect
viable intracellular Mtb. The lysates were cultured on
Middle Brook 7H11 agar medium supplemented with 10%
Middle Brook OADC (oleic acid, albumin, dextrose
and catalase) enrichment (Becton Dickinson, Sparks,
MD, USA). Bacterial viability was calculated by counting
colony forming units (CFU) on agar plates after 21–28 days
of culture at 37°C. Before initiation of any intervention, the
day-0 MDM-mediated killing served as the control
for all groups.
Statistical analysis
Statistical analyses were performed using SigmaStat 3.1 for
Windows (Systat Software Inc., Point Richmond, CA, USA)
and SPSS 17.0 for Windows (SPSS Inc, Chicago, Illinois,
USA). Results were expressed as mean with standard
deviation. Sex and age was matched for each group.
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scatter plots, and normality and homogeneity of vari-
ances were checked by descriptive statistics. Two-way
repeated measure ANOVA was performed when both
the sphericity and normality of the data was met.
When condition for sphericity was violated or normality
of data failed, one Way Analysis of Variance (ANOVA)
was performed followed by the Tukey multiple compari-
son test for between groups and within group variables.
Kruskal-Wallis ANOVA on Ranks was performed
when data was not normally distributed. Analysis of
Co-variance was performed when data at entry level was
significantly different. P-values < 0.05 were considered
significant.
Results
Plasma levels of vitamin D3 and calcium
The average of 25-hydroxyvitamin D3 levels in plasma
increased in all groups except for Group-IV (treated
with only PB). However, the increase was not significant
(Figure 1). Sex and age was matched for each group.
Similarly, no changes were observed in albumin-adjusted
calcium levels during the study period in any of the
groups (data not shown).
SGPT level before treatment was normal in all healthy
volunteers except for one male volunteer in Group-I,
who had 66.49 IU/L that was above the normal upper
range of 56 IU/L. However, the SGPT level (12.08 IU/L)
declined on day-4 to normal level. None of the volun-
teers showed any increase in SGPT level after ingestion
of PB alone or in combination with vitamin D3 on day-4
or −8 (Additional file 1: Table S1).Figure 1 Plasma 25-hydroxyvitamin D3 concentration in healthy adul
5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.
500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. PB: Phenylbutyrate. b.d.: tSynergistic effects of PB and vitamin D3 on LL-37
expression in macrophages
Significant differences in concentration of MDM derived
LL-37 transcripts and peptides were observed within days.
A significant increase in both peptide (p = 0.05) and tran-
script (p = 0.011) was noted in Group-II in day-4 compared
to day-0 (Table 1 and 2). Group-I showed significantly
higher levels of LL-37 transcript but not peptide at day-4
(p = 0.015) and day-8 (p = 0.042) compared to day-0.
Group-IV showed a marginal increase in LL-37 transcript
levels on day-4 compared to day-0 (p = 0.07) (Table 1).
When comparing between groups, Group-I and Group-II
exhibited significantly higher levels of LL-37 transcript on
day-4 compared to Group-III (p = 0.025 and p = 0.03
respectively) and Group-V (p = 0.03 and p = 0.035 respect-
ively) (Table 1). Furthermore, Group-II showed higher levels
of peptide compared to Group-IV (p = 0.01) (Table 2).
PB and vitamin D3 induce LL-37 expression in
lymphocytes
Lymphocyte-derived LL-37 transcript did not show any sig-
nificant induction within days (Table 3). However, LL-37
peptide induction on day-4 was significantly higher in
Group-II compared to Group-I (p = 0.03) and Group-IV
(p = 0.05) (Table 4). Group-IV showed increased production
of peptide on day-8 compared to Group-III (p = 0.03) and
Group-I (p = 0.04).
No effects of PB and vitamin D3 on LL-37 expression in
PBMC
There was no significant induction of LL-37 production
in ECF of total PBMC within days or between groups.ts before and after supplementation. Group-I: 250 mg PB b.d. +
; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-IV:
wice daily. o.d. : once daily. Data were analyzed by One-way ANOVA.
Table 1 Expression of LL-37 transcript in monocyte-derived
macrophages from healthy adults before and after
supplementation
LL-37 transcript (copy no.)
Day-0 Day-4 Day-8
Group-I MDM 9.68 ± 9.0 64.37 ± 19.03a 1,2 21.61 ± 18.71b
Group-II MDM 16.24 ± 1.77 62.42 ± 19.56c 3,4 38.25 ± 15.65
Group-III MDM 10.94 ± 2.01 10.40 ± 16.19 41.05 ± 52.30
Group-IV MDM 8.71 ± 4.64 33.87 ± 16.76 13.42 ± 9.57
Group-V MDM 10.13 ± 5.41 11.54 ± 12.90 8.74 ± 6.27
Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB
b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3
o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d.. Data
expressed as Mean ± Standard Deviation. One Way Analysis of Variance
(ANOVA) method was used for statistical analysis. Differences are significant,
when p < 0.05. Difference between, aday-4 and day-0 within Group-I (p = 0.01);
bday-8 and day-0 within Group-I (p = 0.04); cday-4 and day-0 within Group-II
(p = 0.01); 1Group-I and -III within day-4 (p = 0.02); 2Group-I and -V within day-4
(p = 0.034); 3Group-II and -III within day-4 (p = 0.031); 4Group-II and -V within
day-4 (p = 0.035). PB, Phenylbutyrate; MDM, Monocyte-derived macrophages; b.
d., Twice daily; o.d., Once daily.
Table 3 Expression of LL-37 transcript in non-adherent
lymphocytes in healthy adults before and after
supplementation
LL-37 transcript (copy no.)
Day-0 Day-4 Day-8
Group-I NAL 9.60 ± 2.80 19.5 ± 7.65 7.46 ± 5.00
Group-II NAL 29.57 ± 6.17 54.43 ± 16.48 38.25 ± 20.66
Group-III NAL 19.33 ± 8.21 30.00 ± 10.60 20.00 ± 5.01
Group-IV NAL 14.78 ± 3.08 18.68 ± 5.92 19.12 ± 10.33
Group-V NAL 9.18 ± 2.39 23.30 ± 14.58 20.71 ± 7.45
Note. Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB
b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3
o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data
expressed as Mean ± Standard Deviation. One Way Analysis of Variance
(ANOVA) method was used. Analysis of Co-variance was performed when
significant difference was found at entry level. PB, Phenylbutyrate; NAL,
Non-adherent lymphocytes; b.d., Twice daily; o.d., Once daily.
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any remarkable increase in LL-37 release in the ECF
(0.53 ± 0.17 ng/106 PBMC) compared to the ECF of
unstimulated PBMC (0.50 ± 0.17 ng/106 PBMC) (p = 0.92).
PB and/or vitamin D3 mediate enhanced killing of Mtb
ex vivo
Group-II demonstrated significantly higher intracellular
killing of Mtb by MDM at day-4 (p = 0.027) compared to
day-0. Group-I and -V exhibited a significant increase in
intracellular killing on day-4 (p < 0.001 and p = 0.019 re-
spectively) and day-8 (p < 0.001 and p = 0.051 respectively)
compared to day-0 (Figure 2). The other Groups did not
show any increase in the killing activity of MDM (Figure 2).Table 2 Expression of LL-37 peptide in monocyte-derived
macrophages from healthy adults before and after
supplementation
LL-37 level in ICF (ng/million cells)
Day-0 Day-4 Day-8
Group-I MDM 0.52 ± 0.06 0.72 ± 0.28 0.68 ± 0.19
Group-II MDM 0.33 ± 0.02 1.22 ± 0.49a 1 0.36 ± 0.05
Group-III MDM 0.28 ± 0.00 0.27 ± 0.02 0.27 ± 0.02
Group-IV MDM 0.15 ± 0.02 0.13 ± 0.02 0.16 ± 0.02
Group-V MDM 0.21 ± 0.08 0.20 ± 0.05 0.23 ± 0.09
Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB
b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3
o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data
expressed as Mean ± Standard Deviation. One Way Analysis of Variance
(ANOVA) method was used for statistical analysis. Kruskal-Wallis ANOVA on
Ranks was performed when the data was not normally distributed; analysis of
Co-variance was performed when significant difference was found at entry
level. Differences are significant, when p < 0.05. Difference between, aday-4
and day-0 within Group-II (p = 0.02); 1Group-II and -III within day-4 (p = 0.034).
ICF, Intracellular fluid; PB, Phenylbutyrate; MDM, Monocyte-derived
macrophages; b.d., Twice daily; o.d., Once daily.Discussion
In this study we demonstrated that oral supplementation
of healthy adult volunteers with 500 mg PB b.d. plus
5000 IU vitamin D3 o.d. (Group-II) consistently induced
LL-37 in both macrophages and lymphocytes, and also
exhibited increased MDM derived intracellular killing of
M. tuberculosis.
In an animal model of shigellosis we have previously
shown that Shigella infection causes downregulation of
the rabbit cathelicidin CAP-18 in the epithelia of rectum,
lung and trachea [17,20]. Oral feeding of butyrate
(0.14 mmol/dose) or PB (0.14 mmol/dose) up-regulates
CAP-18 expression in the lung and rectal epithelia of these
rabbits and reduces shedding of Shigella in stool [20]. We
have also demonstrated that PB, induces the CAMP gene
expression synergistically with 1,25-dihydroxyvitamin D3 at
both protein and mRNA levels in the VA10 lung epithelial
cell line [21]. We have now further shown in humans, thatTable 4 Expression of LL-37 peptide in non-adherent
lymphocytes in healthy adults before and after
supplementation
LL-37 level in ICF (ng/million cells)
Day-0 Day-4 Day-8
Group-I NAL 0.24 ± 0.07 0.23 ±0.11 0.18 ± 0.12
Group-II NAL 0.28 ± 0.04 0.49 ± 0.16 1,2 0.33 ± 0.11
Group-III NAL 0.31 ± 0.11 0.25 ± 0.02 0.17 ± 0.06
Group-IV NAL 0.27 ± 0.14 0.21 ± 0.02 0.68 ± 0.32 3,4
Group-V NAL 0.19 ± 0.08 0.37 ± 0.07 0.27 ± 0.15
Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB
b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3
o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data
expressed as Mean ± Standard Deviation. One Way Analysis of Variance
(ANOVA) method was used for statistical analysis. Differences are significant,
when p < 0.05. Difference between, 1Group-II and -I within day-4 (p = 0.05);
2Group-II and -IV within day-4 (p = 0.03); 3Group-IV and -I within day-8
(p = 0.04); 4Group-IV and-III within day-8 (p = 0.036). ICF, Intracellular fluid;
PB, Phenylbutyrate; NAL, Non-adherent lymphocytes; b.d., Twice daily; o.d.,
Once daily.
Figure 2 Viable Mtb CFU count in Monocyte derived macrophages (MDM). MDM from different group of volunteers were incubated with Mtb
H37Rv strain for 2 h, after that extracellular bacteria were removed and cultured for 3 days, cells were lysed and plated for variable colony (CFU) count.
Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3
o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d.. PB: Phenylbutyrate. b.d.: twice daily. o.d. : once daily. The straight horizontal line
indicates means. Data were analyzed by two-way (treatment and time) repeated measures ANOVA. * p < 0.05, and *** p < 0.001.
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can also induce LL-37 in immune cells. In this study, three
potential doses of PB were selected for healthy adults.
Group I (250 mg b.d. with 5000 IU vitamin D3 o.d.) showed
significant increase in LL-37 transcript but not peptide in
MDM; no changes in peptide or transcript was noted in
NAL. Group-II (500 mg b.d. plus 5000 IU vitamin D3 o.d.)
showed increase in both peptide and transcript in MDM
and peptide in NAL. In Group-III with the higher dose of
PB (1 g b.d.) along with vitamin D3 there was no increase
in LL-37 transcript or peptide in cells after PB supplemen-
tation. Butyrate is known to inhibit RNA and protein syn-
thesis at high concentrations [24-26]. We may speculate
that in a similar fashion PB at high doses is inhibitory to
the expression of LL-37 both at transcriptional and transla-
tional levels. The dose of Group-II appears superior in
inducing both peptide and mRNA concentrations in MDM
and peptide in lymphocytes.
Various cell types including T lymphocytes are known
to express LL-37 [27,28]. However, to our knowledge
this is the first study to report enhanced in vivo induc-
tion of LL-37 in lymphocytes after oral supplementation
with PB alone or in combination with vitamin D3. This
finding thus underscores the significance of PB therapy
in TB infection since T cells play a major role in the host
defense against tuberculosis [29].
The present study showed that oral intake of vitamin D3
(Group-V) alone or in combination with PB (Group-I
and -II) exhibited a marked increase in intracellular
killing of Mtb. Vitamin D3-induced LL-37 expressionis an important factor in fighting TB [11,12]. Killing
of Mtb by macrophages is directly correlated with
CAMP gene expression encoding LL-37 and plasma
levels of 25-hydroxyvitamin D3 [12]. Furthermore, it was
shown that activation of Toll-Like Receptor 2/1 in human
macrophages up-regulated expression of the genes encod-
ing vitamin D receptor and vitamin D-hydroxylase, leading
to induction of LL-37 with subsequent killing of intracellu-
lar Mtb [11]. Recent studies have shown that human
cathelicidin is a key mediator of 1,25-dihydroxyvitamin
D3-induced autophagy and hence provide a mechanistic
insight into the role of cathelicidin in combating Mtb
[30,31]. Interestingly, in vitro studies have shown that
short chain fatty acids, butyrate and propionate can
induce both apoptosis and autophagy [32]. PB is an
analogue of butyrate and it is quite likely that PB in com-
bination with Vitamin D3 may also induce autophagy and
LL-37 mediated killing of Mtb ex vivo.
The major limitation of this study is the small sample
size and the short duration of the PB and vitamin
D3 supplementation. The lack of increase in plasma
25-hydroxyvitamin D3 level after 4 days supplementation
was not unexpected since 1–2 months supplementation is
needed to reach steady state vitamin D3 levels.
Conclusion
In conclusion, oral combination dose of 500 mg PB b.d.
with 5000 IU vitamin D3 o.d. appears to be the optimum
dose to induce both LL-37 peptide and transcript expres-
sion in functional immune cells as well as enhance
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http://www.biomedcentral.com/1471-2466/13/23intracellular Mtb killing in macrophages. The dose of
250 mg PB b.d. with 5000 IU vitamin D3 o.d. also
increased intracellular killing however it enhanced only
LL-37 transcript levels (not peptide) in macrophages but
not in lymphocytes. This pilot study has generated results
for a potential dose in a clinical trial of adults with active
pulmonary TB (NCT01580007).
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